Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.
Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.
Int J Antimicrob Agents. 2021 Mar;57(3):106275. doi: 10.1016/j.ijantimicag.2020.106275. Epub 2021 Jan 2.
The COVID-19 pandemic, caused by SARS-CoV-2, has led to a rapid search for therapeutic and preventive measures because of the potentially severe course of infection. The antiviral drug, remdesivir, and the anti-inflammatory agent, dexamethasone, have shown beneficial effects. As the current COVID-19 vaccines are not yet fully available to everyone, or they may not be readily and universally accepted, various treatment options are being evaluated and will still be needed under these conditions. One of these treatment options, passive immunization, has shown promise in some studies. Further research is needed to determine the utility of immunotherapy with convalescent plasma or artificially produced monoclonal antibodies for the treatment of symptomatic patients, and potentially for use as post-exposure prophylaxis, at least until more effective drugs are available or safe and effective vaccines are distributed and administered to everyone.
由 SARS-CoV-2 引起的 COVID-19 大流行，由于感染可能会出现严重的后果，因此人们迅速寻找治疗和预防措施。抗病毒药物瑞德西韦和抗炎药地塞米松已显示出有益的效果。由于目前 COVID-19 疫苗尚未普及，或者人们可能不愿意或无法普遍接受疫苗，因此正在评估各种治疗选择，在这种情况下仍需要这些选择。在这些治疗选择中，被动免疫在一些研究中显示出了前景。还需要进一步的研究来确定使用恢复期血浆或人工产生的单克隆抗体进行免疫治疗对治疗有症状的患者的效果，以及在更有效的药物问世之前，或安全有效的疫苗分发并为每个人接种之前，作为暴露后预防的潜在用途。
